Showing results (11-20 of 149) with videos related to
Sort By:
Pageof 15
Journal of Medicinal Chemistry|February 1, 1990
Nonneurotoxic tetralin and indan analogues of 3,4-(methylenedioxy)amphetamine (MDA)D E Nichols, W K Brewster, M P Johnson, et al.Pharmacology, Biochemistry, and Behavior|February 1, 1986
Studies of the relationship between molecular structure and hallucinogenic activityD E NicholsEuropean Journal of Pharmacology|July 20, 1993
5-HT2 receptor-mediated potentiation of dopamine synthesis and central serotonergic deficitsX Huang, D E NicholsThe Journal of Foot and Ankle Surgery : Official Publication of the American College of Foot and Ankle Surgeons|February 21, 1998
Oat cell carcinoma metastasis to the footL A Delgadillo, D E NicholsJournal of Medicinal Chemistry|May 1, 1982
Isomeric cyclopropyl ring-methylated homologues of trans-2-(2,5-dimethoxy-4-methylphenyl)cyclopropylamine, an hallucinogen analogueJ N Jacob, D E NicholsThe Journal of Pharmacology and Experimental Therapeutics|May 1, 1995
The monoamine oxidase-B inhibitor L-deprenyl protects against 3,4-methylenedioxymethamphetamine-induced lipid peroxidation and long-term serotonergic deficitsJ E Sprague, D E NicholsEuropean Journal of Pharmacology|June 2, 1994
Behavioral effects of the highly selective serotonin releasing agent 5-methoxy-6-methyl-2-aminoindanD Marona-Lewicka, D E NicholsEuropean Journal of Pharmacology|July 23, 1991
Microdialysis studies on 3,4-methylenedioxyamphetamine and structurally related analoguesJ F Nash, D E NicholsPsychopharmacology|April 1, 1995
Inhibition of MAO-B protects against MDMA-induced neurotoxicity in the striatumJ E Sprague, D E NicholsJournal of Medicinal Chemistry|February 1, 1977
Lipophilicity and serotonin agonist activity in a series of 4-substituted mescaline analoguesD E Nichols, D C DyerPageof 15